Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity

Molecular Pharmaceutics

Volumn 6, Issue 5, 2009, Pages 1582-1590

  Adediran, Samusi A ^a   Day, Timothy P ^a   Sil, Diptesh ^a   Kimbrell, Matthew R ^a   Warshakoon, Hemamali J ^a   Malladi, Subbalakshmi S ^a   David, Sunil A ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Aggregation; Amphotericin B; Antifungal; Carbodiimide; Solubility; Toll like receptors; Toxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DERIVATIVE; BIS(DIMETHYLAMINOPROPYL)CARBODIIMIDE; CYANAMIDE; N,N DIMETHYLFORMAMIDE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; WATER;

ABSORPTION SPECTROPHOTOMETRY; ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CONFERENCE PAPER; DRUG SOLUBILITY; ELECTROSPRAY MASS SPECTROMETRY; FUNGUS GROWTH; GROWTH INHIBITION; INFLAMMATION; LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CELL LINE; GENES, REPORTER; HUMANS; INFLAMMATION; KIDNEY; MOLECULAR STRUCTURE; SOLUBILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; WATER;

EID: 70350057598     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp9001602     Document Type: Conference Paper

References (55)

1. Dutcher, J. D. The discovery and development of amphotericin B. Dis. Chest. 1968, 54 (Suppl. 1), 296-298.
2. Chapman, S. W.; Sullivan, D. C.; Cleary, J. D. In search of the holy grail of antifungal therapy. Trans. Am. Clin. Climatol. Assoc. 2008, 119, 197-215; discussion, 215-216.
3. Ellis, D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 2002, 49 (Suppl. 1), 7-10.
4. Herbrecht, R.; Denning, D. W.; Patterson, T. F.; Bennett, J. E.; Greene, R. E.; Oestmann, J. W.; Kern, W. V.; Marr, K. A.; Ribaud, P.; Lortholary, O.; Sylvester, R.; Rubin, R. H.; Wingard, J. R.; Stark, P.; Durand, C.; Caillot, D.; Thiel, E.; Chandrasekar, P. H.; Hodges, M. R.; Schlamm, H. T.; Troke, P. F.; de Pauw, B. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002, 347, 408-415. (Pubitemid 34851833)
5. Powers, J. H.; Dixon, C. A.; Goldberger, M. J. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N. Engl. J. Med. 2002, 346, 289-290. (Pubitemid 34438872)
6. Walsh, T. J.; Pappas, P.; Winston, D. J.; Lazarus, H. M.; Petersen, F.; Raffalli, J.; Yanovich, S.; Stiff, P.; Greenberg, R.; Donowitz, G.; Schuster, M.; Reboli, A.; Wingard, J.; Arndt, C.; Reinhardt, J.; Hadley, S.; Finberg, R.; Laverdiere, M.; Perfect, J.; Garber, G.; Fioritoni, G.; Anaissie, E.; Lee, J. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 2002, 346, 225-234. (Pubitemid 34438861)
7. Smith, W. J.; Drew, R. H.; Perfect, J. R. Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. Expert. Rev. Anti-Infect. Ther. 2009, 7, 165-181.
8. Morris, M. I. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am. J. Health-Syst. Pharm. 2009, 66, 225-236.
9. Garcia-Vidal, C.; Carratala, J. Echinocandins for candidemia. N. Engl. J. Med. 2006, 355, 2791-2792.
10. Bohme, A.; Ruhnke, M.; Buchheidt, D.; Cornely, O. A.; Einsele, H.; Enzensberger, R.; Hebart, H.; Heinz, W.; Junghanss, C.; Karthaus, M.; Kruger, W.; Krug, U.; Kubin, T.; Penack, O.; Reichert, D.; Reuter, S.; Silling, G.; Sudhoff, T.; Ullmann, A. J.; Maschmeyer, G. Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 2009, 88, 97-110.
11. Torrado, J. J.; Espada, R.; Ballesteros, M. P.; Torrado-Santiago, S. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 2008, 97, 2405-2425.
12. Fanos, V.; Cataldi, L. Amphotericin B-induced nephrotoxicity: a review. J. Chemother. 2000, 12, 463-470.
13. Miano-Mason, T. M. Mechanisms and management of amphotericin B-induced nephrotoxicity. Cancer Pract. 1997, 5, 176-181.
14. Saliba, F.; Dupont, B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med. Mycol. 2008, 46, 97-112.
15. Khoo, S. H.; Bond, J.; Denning, D. W. Administering amphotericin B - a practical approach. J. Antimicrob. Chemother. 1994, 33, 203-213.
16. Gallis, H. A.; Drew, R. H.; Pickard, W. W. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 1990, 12, 308-329.
17. Berman, J. ABLE: a new and improved amphotericin B for visceral leishmaniasis? Am. J. Trop. Med. Hyg. 2009, 80, 689-690.
18. Thornton, S. J.; Wasan, K. M. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert. Opin. Drug Delivery 2009, 6, 271-284.
19. Gruda, I.; Milette, D.; Brother, M.; Kobayashi, G. S.; Medoff, G.; Brajtburg, J. Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose. Antimicrob. Agents Chemother. 1991, 35, 24-28.
20. Tancrede, P.; Barwicz, J.; Jutras, S.; Gruda, I. The effect of surfactants on the aggregation state of amphotericin B. Biochim. Biophys. Acta 1990, 1030, 289-295.
21. Barwicz, J.; Christian, S.; Gruda, I. Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob. Agents Chemother. 1992, 36, 2310-2315.
22. Legrand, P.; Romero, E. A.; Cohen, B. E.; Bolard, J. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob. Agents Chemother. 1992, 36, 2518-2522.
23. Paquet, V.; Carreira, E. M. Significant improvement of antifungal activity of polyene macrolides by bisalkylation of the mycosamine. Org. Lett. 2006, 8, 1807-1809.
24. Paquet, V.; Volmer, A. A.; Carreira, E. M. Synthesis and in vitro biological properties of novel cationic derivatives of amphotericin B. Chemistry 2008, 14, 2465-2481.
25. Zumbuehl, A.; Stano, P.; Sohrmann, M.; Peter, M.; Walde, P.; Carreira, E. M. A novel strategy for bioconjugation: synthesis and preliminary evaluation with amphotericin B. Org. Biomol. Chem. 2007, 5, 1339-1342. (Pubitemid 46674868)
26. Sheehan, J. C.; Cruickshank, P. A.; Boshart, G. L. A convenient synthesis of water-soluble carbodiimides. J. Org. Chem. 1961, 26, 2525-2528.
27. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution Clin. Microbiol. Infect. 2003, 9, 1-7.
28. Balakrishna, R.; Wood, S. J.; Nguyen, T. B.; Miller, K. A.; Suresh Kumar, E. V.; Datta, A.; David, S. A. Structural correlates of antibacterialandmembrane-permeabilizingactivitiesinacylpolyamines. Antimicrob. Agents Chemother. 2006, 50, 852-861.
29. Kimbrell, M. R.; Warshakoon, H.; Cromer, J. R.; Malladi, S.; Hood, J. D.; Balakrishna, R.; Scholdberg, T. A.; David, S. A. Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells. Immunol. Lett. 2008, 118, 132-141.
30. Sil, D.; Shrestha, A.; Kimbrell, M. R.; Nguyen, T. B.; Adisechan, A. K.; Balakrishna, R.; Abbo, B. G.; Malladi, S.; Miller, K. A.; Short, S.; Cromer, J. R.; Arora, S.; Datta, A.; David, S. A. Bound to Shock: Protection from Lethal Endotoxemic Shock by a Novel, Nontoxic, Alkylpolyamine Lipopolysaccharide Sequestrant. Antimicrob. Agents Chemother. 2007, 51, 2811-2819. (Pubitemid 47206216)
31. Wu, W.; Sil, D.; Szostak, M. L.; Malladi, S. S.; Warshakoon, H. J.; Kimbrell, M. R.; Cromer, J. R.; David, S. A. Structure-activity relationships of lipopolysaccharide sequestration in guanylhydrazone- bearing lipopolyamines. Bioorg. Med. Chem. 2008, 17 (2), 709-715.
32. Miller, K. A.; Suresh Kumar, E. V. K.; Wood, S. J.; Cromer, J. R.; Datta, A.; David, S. A. Lipopolysaccharide Sequestrants: Structural Correlates of Activity and Toxicity in Novel Acylhomospermines. J. Med. Chem. 2005, 48, 2589-2599.
33. Nakajima, N.; Ikada, Y. Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media. Bioconjugate Chem. 1995, 6, 123-130.
34. Izdebski, J.; Orlowska, A.; Anulewicz, R.; Witkowska, E.; Fiertek, D. Reinvestigation of the reactions of carbodiimides with alkoxycarbonylamino acid symmetrical anhydrides. Isolation of two N-acylureas. Int. J. Pept. Protein Res 1994, 43, 184-189. (Pubitemid 24077496)
35. Iwasawa, T.; Wash, P.; Gibson, C.; Rebek, J. Reaction of an Introverted Carboxylic Acid with Carbodiimide. Tetrahedron 2007, 63, 6506-6511. (Pubitemid 46817624)
36. Hopkins, T. P.; Dener, J. M.; Boldi, A. M. Solid-phase synthesis of trisubsituted guanidines. J. Comb. Chem. 2002, 4, 167-174.
37. Rowley, C. N.; Ong, T. G.; Priem, J.; Richeson, D. S.; Woo, T. K. Analysis of the Critical Step in Catalytic Carbodiimide Transformation: Proton Transfer from Amines, Phosphines, and Alkynes to Guanidinates, Phosphaguanidinates, and Propiolamidinates with Li and Al Catalysts. Inorg. Chem. 2008, 47, 12024-12031.
38. Adams, M.; Kwon, G. S. Spectroscopic investigation of the aggregation state of amphotericin B during loading, freeze-drying, and reconstitution of polymeric micelles. J. Pharm. Pharm. Sci. 2004, 7, 1-6.
39. Sanchez-Brunete, J. A.; Dea, M. A.; Rama, S.; Bolas, F.; Alunda, J. M.; Torrado-Santiago, S.; Torrado, J. J. Amphotericin B molecular organization as an essential factor to improve activity/ toxicity ratio in the treatment of visceral leishmaniasis. J. Drug Targeting 2004, 12, 453-460.
40. Bolard, J. How do the polyene macrolide antibiotics affect the cellular membrane properties. Biochim. Biophys. Acta 1986, 864, 257-304.
41. Bolard, J. Interaction of polyene antibiotics with membrane lipids: physicochemical studies of the molecular basis of selectivity. Drugs Exp. Clin. Res. 1986, 12, 613-618. (Pubitemid 16036277)
42. Bolard, J.; Legrand, P.; Heitz, F.; Cybulska, B. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 1991, 30, 5707-5715.
43. Sanchez-Brunete, J. A.; Dea, M. A.; Rama, S.; Bolas, F.; Alunda, J. M.; Torrado-Santiago, S.; Torrado, J. J. Amphotericin B molecular organization as an essential factor to improve activity/ toxicity ratio in the treatment of visceral leishmaniasis. J. Drug Targeting 2004, 12, 453-460.
44. Meletiadis, J.; Chanock, S.; Walsh, T. J. Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. Pharmacogenomics 2008, 9, 561-584.
45. Sau, K.; Mambula, S. S.; Latz, E.; Henneke, P.; Golenbock, D. T.; Levitz, S. M. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14- dependent mechanism. J. Biol. Chem. 2003, 278, 37561-37568.
46. Razonable, R. R.; Henault, M.; Lee, L. N.; Laethem, C.; Johnston, P. A.; Watson, H. L.; Paya, C. V. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob. Agents Chemother. 2005, 49, 1617-1621.
47. Bellocchio, S.; Gaziano, R.; Bozza, S.; Rossi, G.; Montagnoli, C.; Perruccio, K.; Calvitti, M.; Pitzurra, L.; Romani, L. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 2005, 55, 214-222. (Pubitemid 40331148)
48. Adedoyin, A.; Bernardo, J. F.; Swenson, C. E.; Bolsack, L. E.; Horwith, G.; DeWit, S.; Kelly, E.; Klasterksy, J.; Sculier, J. P.; DeValeriola, D.; Anaissie, E.; Lopez-Berestein, G.; Llanos- Cuentas, A.; Boyle, A.; Branch, R. A. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob. Agents Chemother. 1997, 41, 2201-2208.
49. Adedoyin, A.; Swenson, C. E.; Bolcsak, L. E.; Hellmann, A.; Radowska, D.; Horwith, G.; Janoff, A. S.; Branch, R. A. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob. Agents Chemother. 2000, 44, 2900-2902.
50. Bekersky, I.; Fielding, R. M.; Dressler, D. E.; Lee, J. W.; Buell, D. N.; Walsh, T. J. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 2002, 46, 828-833.
51. Bekersky, I.; Fielding, R. M.; Dressler, D. E.; Lee, J. W.; Buell, D. N.; Walsh, T. J. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 2002, 46, 834-840.
52. Sterzel, R. B.; Schulze-Lohoff, E.; Marx, M. Cytokines and mesangial cells. Kidney Int. Suppl. 1993, 39, S26-S31.
53. Radeke, H. H.; Resch, K. The inflammatory function of renal glomerular mesangial cells and their interaction with the cellular immune system. Clin. Invest. 1992, 70, 825-842.
54. Akira, S.; Hirano, T.; Taga, T.; Kishimoto, T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990, 4, 2860-2867. (Pubitemid 120012532)
55. Gomez-Guerrero, C.; Hernandez-Vargas, P.; Lopez-Franco, O.; Ortiz-Munoz, G.; Egido, J. Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches. Curr. Drug Targets: Inflammation Allergy 2005, 4, 341-351. (Pubitemid 40873122)